UNSPSC 51201816: Impromidine

This classification denotes an anti-lipidemic agent with the molecular formula C14H23N7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 931L4X5WMM, chemically known as guanidine, n-(3-(1h-imidazol-4-yl)propyl)-n-(2-(((5-methyl-1h-imidazol-4-yl)methyl)thio)ethyl)- but generally known as impromidine, which bears US NIH Compound Identifier 41376. European Medicines Agency schedules Impromidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08159MIG.

UNSPSC 51201816 Impromidine, a Commodity code, encompasses pharmaceutical products including vaccines; state and local health departments solicit these products through sole-source notices and competitive procurement vehicles to support public health immunization and disease-prevention programs. The Mississippi State Department of Health posted a sole-source procurement notice on July 13, 2026 for Yellow Fever Vaccine from Sanofi Pasteur, Inc., with objections to sole-source classification due August 3, 2026. The notice invited any vendor or entity to demonstrate that alternative sources can supply the vaccine; if substantiated objections were received, the department committed to conduct a competitive bid or selection process rather than proceed with sole-source award. No quantity, contract term, estimated value, or pricing was disclosed in the notice.

The source records only one recent state-local opportunity under this code, limiting visibility into geographic spread and the issuing-body mix. The single posted solicitation involved a state health department pursuing a vaccine procurement through a sole-source review process rather than open competitive solicitation. Without additional recent opportunities in the dataset, the code shows minimal activity at the state and local level as captured here.